Reinnervate and Oncotest enter collaboration agreement
Reinnervate Ltd announced that it has entered into a co-marketing agreement with the pre-clinical Oncology CRO Oncotest GmbH.
Under the terms of the partnership, Oncotest will offer automated assays based on Alvetex®Scaffold technology, complementing their 3D Tumour Clonogenic Assay technology.
Prof. Stefan Przyborski, founder and CSO of Reinnervate described the benefits of the 96 well plates for cancer cell cytotoxicity testing:"The Alvetex®Scaffold 96 well plate allows scientists to grow tumour cells in 3D, better mimicking the way these cells grow in vivo. It is very easy to start using 3D cell culture with Alvetex® technology. You simply seed the cells, add your existing media and place in your standard incubator. There is no struggling with new and sometimes cumbersome protocols required with other 3D technologies such as collagen gels or hanging drops."
Other news from the department business & finance
